Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 14/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.91 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalapril SCHEMBL28322902 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13575793 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8089096 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL13933092 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL18 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL6159149 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL97 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL474012 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL8433334 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 | |
| Enalapril SCHEMBL28323975 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2ABCB11MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022083644-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | PD BIOMEDICAL CO., LTD. (CN) | 2022-04-28 | — | — | WO | disclosed |
| US-20220117936-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | PIN JYE BIO TECH CO., LTD. (TW) | 2022-04-21 | — | — | US | disclosed |
| EP-2903690-B1 | ENALAPRIL COMPOSITIONS | SILVERGATE PHARMACEUTICALS INC (US) | 2020-01-22 | — | — | EP | disclosed |
| WO-2017161339-A1 | ENALAPRIL FORMULATIONS | Silvergate Pharmaceuticals, Inc. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-7858611-B2 | Neurogenesis by modulating angiotensin | BRAINCELLS INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20100029734-A1 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009137543-A2 | METHODS FOR BREAST CANCER SCREENING AND TREATMENT | ORE PHARMACEUTICALS INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090155245-A1 | Treatment for Organ Regeneration with Combination of Drug and Biologics | DEPUY ORTHOPAEDICS, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-2021000-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | Braincells, Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2007134136-A2 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-5929251-A | Process for the preparation of carboxylic acid succinimidyl esters | DSM FINE CHEMICALS AUSTRIA GMBH (AU) | 1999-07-27 | — | — | US | disclosed |
| US-5734064-A | Process for the preparation of carboxylic acid succinimidyl esters | DSM CHEMIE LINZ GMBH (AT) | 1998-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213172-A1 | RADIOIMAGING MOIETIES COUPLED TO PEPTIDEASE-BINDING MOIETIES FOR IMAGING TISSUES AND ORGANS THAT EXPRESS PEPTIDASES | LAP3, DNPEP, ACE | ACE 3/4885LMNA 449/4885SMN1; SMN2 3297/4885 |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885LMNA 3688/4885SMN1; SMN2 138/4885 |
| US-20110092464-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885LMNA 2026/4885SMN1; SMN2 540/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885LMNA 2155/4885SMN1; SMN2 907/4885 |
| US-20220117936-A1 | BIOSENSING PLATFORM FOR DETECTING VIRAL INFECTIONS AND METHODS FOR SCREENING A MODULATOR OF VIRAL INFECTIONS AND PROTECTING THEREFROM | ACE2, ACE, TMPRSS2 | ACE 2/4885LMNA 2287/4885SMN1; SMN2 4127/4885 |
| US-20080167291-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | DCX, NGF, BDNF | ACE 10/4885LMNA 2061/4885SMN1; SMN2 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.